Sitilop is collaborating with Life Molecular Imaging and Invicro on a new way of evaluating Tau depositions in Progressive Supranuclear Palsy

Progressive Supranuclear Palsy is a rare neurodegenerative disorder characterised by the presence of 4-repeat tau pathology. Progressive Supranuclear Palsy is regarded as a spectrum of different phenotypes characterised by predominant motor, cognitive, speech, or behavioural impairment. No therapy is available for this disease and symptomatic treatment offers only limited benefit. Sitilop is collaborating with Life…